The primary objective of this study is:
• To examine the pharmacokinetics (PK) of cefazolin in children aged 10 to 12 years
(inclusive) receiving weight-dependent 1gram (g) or 2g of cefazolin intravenous (IV)
delivered over 30 minutes via the DUPLEX® drug delivery system for surgical prophylaxis.
The secondary objectives of this study are:
- To compare the PK data in children aged 10 to 12 years (inclusive)receiving 1g or 2g of
cefazolin IV delivered over 30 minutes via the DUPLEX® drug delivery system with
modeling data for adolescents aged 13-17 years (inclusive) and historical data from
adults receiving a single 2g dose of cefazolin.
- To assess the safety of a single dose of cefazolin in children aged 10 to 12 years
(inclusive) receiving 1g or 2g of cefazolin IV delivered over 30 minutes via the DUPLEX®
drug delivery system for surgical prophylaxis.